Your AI-Trained Oncology Knowledge Connection!
Christian Marth, MD, PhD discusses long-term efficacy and safety results from KEYNOTE-775 and LEAP-001. Data include patients with advanced or recurrent endometrial cancer after prior systemic therapy. Follow-up duration was approximately 5 years for KEYNOTE-775 and 4 years for LEAP-001.
Tiffany Traina, MD, FASCO, highlights results from the phase 3 TROPION-Breast02 trial showing that datopotamab deruxtecan significantly improved progression-free and overall survival versus chemotherapy in patients with previously untreated triple-negative breast cancer who were not eligible for immunotherapy.
Misty D. Shields, MD, PhD, reviews primary findings from the IDeate-Lung01 trial, highlighting the promising systemic and intracranial efficacy and manageable safety profile of ifinatamab deruxtecan (I-DXd) in patients with extensive-stage small cell lung cancer, including those with baseline brain metastases.
Summarize long-term results from the phase 2 EDGE-Gastric Arm A1 study evaluating domvanalimab (anti-TIGIT) + zimberelimab (anti-PD-1) + FOLFOX as first-line therapy for advanced HER2-negative gastric, GEJ, or esophageal adenocarcinoma. Key data shown include ORR, PFS, OS, and safety outcomes, demonstrating encouraging clinical activity and manageable toxicity, along with context regarding the ongoing phase 3 STAR-221 trial.
Sikander Ailawadhi, MD, reviews patient experience and satisfaction findings from the phase 3 IRAKLIA study comparing subcutaneous isatuximab via on-body injector with intravenous isatuximab in relapsed or refractory multiple myeloma.
Alison M. Schram, MD, of Memorial Sloan Kettering Cancer Center, discusses initial results from the pivotal Phase 2 PYNNACLE trial evaluating rezatapopt, a first-in-class p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation.
Seth Wander, MD, PhD discusses an overview of emerging data and evolving treatment strategies in advanced gastric and gastroesophageal cancers, with a focus on the role of biomarkers in guiding targeted and immunotherapy-based treatment. The presentation highlights clinical trial outcomes, testing considerations, and future directions shaping the personalized management of these patients.
Laura Huppert, MD discusses LBA20 – primary results from ASCENT-03: a randomized phase 3 study of Sacituzumab Govitecan (SG) vs chemotherapy (Chemo) in patients (Pts) with previously untreated Advanced Triple-Negative Breast Cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i)
An expert discusses Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05
An expert discusses updated overall survival results from the phase 2 PHAROS study evaluating encorafenib plus binimetinib in patients with BRAF V600E–mutant metastatic non–small cell lung cancer (mNSCLC).
Shanu Modi, MD discusses key results from the DESTINY-Breast11 trial for high-risk HER+ early breast cancer.
Lead presenter Passi Jaane, MD, PhD presents key data on the FLAURA2 trial presented at ESMO 2025.
Karolina Faysman, RN, MSN, AOCNP, DNPc, highlights efficacy, safety, and patient-reported outcomes from the phase 2 AGAVE-201 trial evaluating axatilimab for chronic graft-versus-host disease.
Gurdeep Parmar, MBBS, MD, FRCPA, FRACP, discusses patient experience and preference findings from the phase 2 IZALCO study evaluating subcutaneous isatuximab administered via on-body injector in relapsed/refractory multiple myeloma.
To describe clinical outcomes of both Y-90 RS and EBRT as initial therapy for solitary HCC.
Ross Camidge, MD, PhD, discusses a pivotal phase 2/3 clinical trial (ARROS-1) evaluating the efficacy and safety of zidesamtinib in patients with advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who have previously received tyrosine kinase inhibitor (TKI) therapy.
Martin Dietrich, MD, PhD presents insights from an exploratory analysis of the Phase I/II SOHO-01 trial of sevabertinib in HER2-mutant NSCLC, highlighting how clinical and molecular factors, such as prior therapy, HER2 subtype, and TP53 co-alterations, impact treatment outcomes.
Asher Chanan-Khan, MD, discusses an analysis from the ALPINE trial showing that zanubrutinib reduced the number needed to treat to avoid one progression or death compared with ibrutinib in relapsed/refractory chronic lymphocytic leukemia, with results also demonstrating substantial cost savings from a US payer perspective
Expert reviews favorable efficacy and durability 5-year results for cemiplimab plus chemotherapy versus chemotherapy in the EMPOWER-Lung 3 Part 2 trial.
Naveen Pemmaraju, MD, reviews subgroup analyses of tagraxofusp as first-line therapy in BPDCN, highlighting durable responses and successful transplant bridging across age and fitness groups
Jacob Sands, MD, provides a post hoc analysis of TROPION-Lung01 , which showed improved intracranial activity and progression-free survival with datopotamab deruxtecan (Dato-DXd) versus docetaxel. Among patients with measurable brain metastases, Dato-DXd achieved a central nervous system confirmed overall response rate of 38%, with all evaluable patients showing disease control. No intracranial responses were seen in the docetaxel arm.
Presented by Dr. Hope S. Rugo, this slide deck presents updated phase 1b/2 safety and efficacy results from the ELEVATE trial of elacestrant combinations with ribociclib and everolimus in ER+/HER2- metastatic breast cancer, highlighting their clinical activity and potential as an endocrine therapy backbone.
Presented by Dr. Pankit Vachhani, this updated analysis of the PIONEER trial demonstrated that long-term treatment with avapritinib led to sustained symptom relief, improved quality of life, and maintained a favorable safety profile over approximately 3 years in patients with indolent systemic mastocytosis.
Presented by Dr. Thomas Martin, this IMROZ subgroup analysis demonstrated that adding isatuximab to standard VRd therapy improved progression-free survival and deepened responses in transplant-ineligible patients with newly diagnosed multiple myeloma and 1q21+ status, a high-risk cytogenetic subgroup.
The Phase 3 IMforte trial demonstrated that maintenance therapy with lurbinectedin plus atezolizumab was well tolerated and explored a novel approach to extending disease control following first-line treatment in patients with extensive-stage small cell lung cancer.
Lydia Scarfò, MD, presented updated phase 1 data from the CaDAnCe-101 study showing that BGB-16673, a novel BTK degrader, demonstrated a manageable safety profile and durable responses in heavily pretreated patients with R/R CLL/SLL, including those with prior BTKi exposure and high-risk mutations.
Jae Park, MD, presents long-term follow-up data from the FELIX study showing sustained remission in a subset of adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with obecabtagene autoleucel (obe-cel), with predictors of long-term benefit and no new safety concerns identified.
Presented by Talha Munir, MBChB, PhD, this matching-adjusted indirect comparison demonstrated a significant progression-free survival advantage for zanubrutinib over fixed-duration acalabrutinib plus venetoclax in low-risk, treatment-naive chronic lymphocytic leukemia, with a 36-month progression-free survival rate of 88.5% vs 77%, respectively.
